|
AR028385A1
(es)
*
|
2000-04-28 |
2003-05-07 |
Acadia Pharm Inc |
Agonistas muscarinicos
|
|
WO2004089942A2
(en)
*
|
2001-10-02 |
2004-10-21 |
Acadia Pharmaceuticals Inc. |
Benzimidazolidinone derivatives as muscarinic agents
|
|
US6951849B2
(en)
|
2001-10-02 |
2005-10-04 |
Acadia Pharmaceuticals Inc. |
Benzimidazolidinone derivatives as muscarinic agents
|
|
BR0213611A
(pt)
|
2001-10-02 |
2005-12-20 |
Acadia Pharm Inc |
Composto, composição farmacêutica, seus usos, método para aumentar a atividade de um receptor colinérgico, métodos para tratamento ou prevenção de distúrbio mental, dor, pressão intraocular aumentada e progressão ou formação de placas amilóides
|
|
US7550459B2
(en)
|
2001-12-28 |
2009-06-23 |
Acadia Pharmaceuticals, Inc. |
Tetrahydroquinoline analogues as muscarinic agonists
|
|
ES2251624T3
(es)
*
|
2001-12-28 |
2006-05-01 |
Acadia Pharmaceuticals Inc. |
Analogos de la tetrahidroquinolina como los agonistas muscarinicos.
|
|
CA2492305A1
(en)
|
2002-07-31 |
2004-02-05 |
Euro-Celtique S.A. |
Aryl substituted benzimidazoles and their use as sodium channel blockers
|
|
US20050250767A1
(en)
*
|
2003-01-23 |
2005-11-10 |
Weiner David M |
Use of N-desmethylclozapine to treat human neuropsychiatric disease
|
|
JP2006515628A
(ja)
*
|
2003-01-23 |
2006-06-01 |
アカディア ファーマシューティカルズ，インコーポレーテッド |
ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用
|
|
US20050085463A1
(en)
*
|
2003-01-23 |
2005-04-21 |
Weiner David M. |
Use of N-desmethylclozapine to treat human neuropsychiatric disease
|
|
WO2004069828A1
(ja)
*
|
2003-02-04 |
2004-08-19 |
Mitsubishi Pharma Corporation |
ピペリジン化合物およびその医薬用途
|
|
WO2004073639A2
(en)
*
|
2003-02-19 |
2004-09-02 |
Merck & Co. Inc. |
Treatment of psychosis with a muscarinic m1 receptor ectopic activator
|
|
NZ542690A
(en)
*
|
2003-03-28 |
2009-04-30 |
Acadia Pharm Inc |
Muscarinic M1 receptor agonists for pain management
|
|
WO2004100947A2
(en)
|
2003-05-06 |
2004-11-25 |
Smithkline Beecham Corporation |
Novel chemical compounds
|
|
EP1677791A4
(en)
|
2003-10-31 |
2007-08-15 |
Takeda Pharmaceutical |
NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS
|
|
AU2004290499C1
(en)
|
2003-11-03 |
2011-02-24 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
|
GB0328295D0
(en)
*
|
2003-12-05 |
2004-01-07 |
Muscagen Ltd |
Therapeutic compounds
|
|
PT1696931E
(pt)
*
|
2003-12-22 |
2009-06-12 |
Acadia Pharm Inc |
Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
|
|
BRPI0509524A
(pt)
*
|
2004-04-01 |
2007-09-18 |
Acadia Pharm Inc |
formas cristalinas de n-desmetilclozapina
|
|
KR20070034049A
(ko)
|
2004-06-09 |
2007-03-27 |
글락소 그룹 리미티드 |
피롤로피리딘 유도체
|
|
WO2006019497A2
(en)
|
2004-06-17 |
2006-02-23 |
Neurocrine Biosciences, Inc. |
Sleep-inducing compounds and methods related thereto
|
|
AR050253A1
(es)
|
2004-06-24 |
2006-10-11 |
Smithkline Beecham Corp |
Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
|
|
JO2724B1
(en)
*
|
2004-08-19 |
2013-09-15 |
افينتس فارماسوتيكالز انك |
3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
|
|
PE20060748A1
(es)
|
2004-09-21 |
2006-10-01 |
Smithkline Beecham Corp |
Derivados de indolcarboxamida como inhibidores de quinasa ikk2
|
|
ES2349416T3
(es)
*
|
2004-10-25 |
2011-01-03 |
Eli Lilly And Company |
Tienopiridinas como potenciadores alostéricos del receptor muscarínico m4.
|
|
JP2008521821A
(ja)
*
|
2004-11-29 |
2008-06-26 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ムスカリン受容体のモジュレーター
|
|
EP1863490A2
(en)
*
|
2005-03-28 |
2007-12-12 |
Vertex Pharmaceuticals Incorporated |
Muscarinic modulators
|
|
US20060258691A1
(en)
*
|
2005-05-13 |
2006-11-16 |
Joseph Barbosa |
Methods and compositions for improving cognition
|
|
US8063071B2
(en)
|
2007-10-31 |
2011-11-22 |
GlaxoSmithKline, LLC |
Chemical compounds
|
|
CA2619972A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Lexicon Pharmaceuticals, Inc. |
Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use
|
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
EP2275095A3
(en)
|
2005-08-26 |
2011-08-17 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
WO2007053618A1
(en)
*
|
2005-10-31 |
2007-05-10 |
Acadia Pharmaceuticals Inc. |
Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
|
|
NL2000291C2
(nl)
|
2005-11-10 |
2009-02-17 |
Pfizer Prod Inc |
1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
|
|
AU2007292848A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
PE20081889A1
(es)
|
2007-03-23 |
2009-03-05 |
Smithkline Beecham Corp |
Indol carboxamidas como inhibidores de ikk2
|
|
US8173672B2
(en)
*
|
2008-03-21 |
2012-05-08 |
Merck Sharp & Dohme Corp. |
Quinolizidinone M1 receptor positive allosteric modulators
|
|
UA103195C2
(uk)
|
2008-08-11 |
2013-09-25 |
Глаксосмитклайн Ллк |
Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
|
|
WO2010102968A1
(en)
|
2009-03-10 |
2010-09-16 |
Glaxo Group Limited |
Indole derivatives as ikk2 inhibitors
|
|
EP2408448A4
(en)
*
|
2009-03-18 |
2012-09-19 |
Univ Leland Stanford Junior |
METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS
|
|
KR20120117905A
(ko)
|
2010-01-28 |
2012-10-24 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
프로테아좀 활성을 향상시키는 조성물 및 방법
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
HUE044867T2
(hu)
|
2011-05-12 |
2019-11-28 |
Proteostasis Therapeutics Inc |
Proteosztázis szabályzók
|
|
HRP20181667T1
(hr)
|
2011-07-22 |
2018-12-14 |
Glaxosmithkline Llc |
Pripravak
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
RU2502743C1
(ru)
*
|
2012-08-03 |
2013-12-27 |
Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) |
Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
EA026354B1
(ru)
|
2012-08-24 |
2017-03-31 |
ГЛАКСОСМИТКЛАЙН ЭлЭлСи |
Пиразолопиримидиновые соединения
|
|
AU2013348217B2
(en)
|
2012-11-20 |
2016-10-06 |
Glaxosmithkline Llc |
Novel compounds
|
|
EA028480B1
(ru)
|
2012-11-20 |
2017-11-30 |
ГЛАКСОСМИТКЛАЙН ЭлЭлСи |
Новые соединения
|
|
BR112015011439A2
(pt)
|
2012-11-20 |
2017-07-11 |
Glaxosmithkline Llc |
composto, composição farmacêutica, composição de vacina, e, uso de um composto
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9849135B2
(en)
|
2013-01-25 |
2017-12-26 |
President And Fellows Of Harvard College |
USP14 inhibitors for treating or preventing viral infections
|
|
AU2014240139A1
(en)
|
2013-03-15 |
2015-09-17 |
Acadia Pharmaceuticals Inc. |
Muscarinic agonists
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2015073528A1
(en)
|
2013-11-12 |
2015-05-21 |
Proteostasis Therapeutics, Inc. |
Proteasome activity enhancing compounds
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
WO2016100940A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute, Inc. |
Dopamine d2 receptor ligands
|
|
US10752588B2
(en)
|
2014-12-19 |
2020-08-25 |
The Broad Institute, Inc. |
Dopamine D2 receptor ligands
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
TWI712601B
(zh)
|
2015-02-20 |
2020-12-11 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
JP6368270B2
(ja)
*
|
2015-04-02 |
2018-08-01 |
株式会社エヌ・ティー・エイチ |
モニエロサイドａ及びその誘導体、又はそれを有効成分として含有する医薬用組成物、健康食品又は化粧品
|
|
US10730842B2
(en)
*
|
2015-09-03 |
2020-08-04 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Small molecule inhibitors of DYRK1A and uses thereof
|
|
EP3416639B1
(en)
|
2016-02-16 |
2022-06-08 |
Vanderbilt University |
Positive allosteric modulators of the muscarinic acetylcholine receptor m1
|
|
GB201616839D0
(en)
*
|
2016-10-04 |
2016-11-16 |
Takeda Pharmaceutical Company Limited |
Therapeutic compounds
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
US12528810B2
(en)
|
2018-03-01 |
2026-01-20 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Small molecule inhibitors of DYRK/CLK and uses thereof
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
WO2019241467A1
(en)
|
2018-06-13 |
2019-12-19 |
Vanderbilt University |
Positive allosteric modulators of the muscarinic acetylcholine receptor m1
|
|
US12065433B2
(en)
|
2018-10-24 |
2024-08-20 |
Vanderbilt University |
Positive allosteric modulators of the muscarinic acetylcholine receptor M1
|
|
US11591323B2
(en)
*
|
2019-03-06 |
2023-02-28 |
Barry university |
Muscarinic agonists as non-steroidal and non-opioid analgesics and methods of use thereof
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3157361A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の誘導体
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
WO2023114224A1
(en)
|
2021-12-13 |
2023-06-22 |
Sage Therapeutics, Inc. |
Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
|
|
WO2025000053A1
(en)
*
|
2023-06-28 |
2025-01-02 |
Psylo Pty Ltd |
Compounds
|